BlackRock’s Autolus Therapeutics AUTL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.57M | Buy |
1,603,458
+122,726
| +8% | +$193K | ﹤0.01% | 4097 |
|
|
2026
Q1 | $2.04M | Sell |
1,480,732
-2,205,093
| -60% | -$3.35M | ﹤0.01% | 4131 |
|
|
2025
Q4 | $7.33M | Buy |
3,685,825
+211,050
| +6% | +$324K | ﹤0.01% | 3655 |
|
|
2025
Q3 | $5.66M | Sell |
3,474,775
-16,361
| -0.5% | -$32K | ﹤0.01% | 3726 |
|
|
2025
Q2 | $7.96M | Sell |
3,491,136
-453,698
| -12% | -$750K | ﹤0.01% | 3540 |
|
|
2025
Q1 | $6.11M | Sell |
3,944,834
-183,116
| -4% | -$372K | ﹤0.01% | 3558 |
|
|
2024
Q4 | $9.7M | Sell |
4,127,950
-297,796
| -7% | -$1.01M | ﹤0.01% | 3446 |
|
|
2024
Q3 | $16.1M | Sell |
4,425,746
-10,356
| -0.2% | -$41.3K | ﹤0.01% | 3173 |
|
|
2024
Q2 | $15.4M | Buy |
4,436,102
+380,182
| +9% | +$1.64M | ﹤0.01% | 3133 |
|
|
2024
Q1 | $25.9M | Buy |
4,055,920
+2,700,581
| +199% | +$16.8M | ﹤0.01% | 2836 |
|
|
2023
Q4 | $8.73M | Buy |
1,355,339
+588,242
| +77% | +$2.24M | ﹤0.01% | 3465 |
|
|
2023
Q3 | $1.79M | Sell |
767,097
-103,897
| -12% | -$296K | ﹤0.01% | 4037 |
|
|
2023
Q2 | $2.07M | Sell |
870,994
-14,503
| -2% | -$34.4K | ﹤0.01% | 4042 |
|
|
2023
Q1 | $1.63M | Buy |
885,497
+473,247
| +115% | +$925K | ﹤0.01% | 4143 |
|
|
2022
Q4 | $783K | Sell |
412,250
-34,605
| -8% | -$87.5K | ﹤0.01% | 4490 |
|
|
2022
Q3 | $956K | Sell |
446,855
-20,991
| -4% | -$62.2K | ﹤0.01% | 4491 |
|
|
2022
Q2 | $1.32M | Buy |
467,846
+81,132
| +21% | +$247K | ﹤0.01% | 4420 |
|
|
2022
Q1 | $1.61M | Sell |
386,714
-85,019
| -18% | -$358K | ﹤0.01% | 4475 |
|
|
2021
Q4 | $2.45M | Buy |
471,733
+321,761
| +215% | +$1.93M | ﹤0.01% | 4326 |
|
|
2021
Q3 | $983K | Buy |
149,972
+95,131
| +173% | +$601K | ﹤0.01% | 4564 |
|
|
2021
Q2 | $364K | Sell |
54,841
-242,764
| -82% | -$1.51M | ﹤0.01% | 4772 |
|
|
2021
Q1 | $1.71M | Sell |
297,605
-2,655
| -0.9% | -$19.7K | ﹤0.01% | 4335 |
|
|
2020
Q4 | $2.68M | Sell |
300,260
-25,830
| -8% | -$275K | ﹤0.01% | 3944 |
|
|
2020
Q3 | $3.79M | Sell |
326,090
-23,956
| -7% | -$347K | ﹤0.01% | 3690 |
|
|
2020
Q2 | $5.61M | Buy |
350,046
+123,179
| +54% | +$1.37M | ﹤0.01% | 3473 |
|
|
2020
Q1 | $1.36M | Sell |
226,867
-15,643
| -6% | -$145K | ﹤0.01% | 3777 |
|
|
2019
Q4 | $3.2M | Sell |
242,510
-16,214
| -6% | -$212K | ﹤0.01% | 3635 |
|
|
2019
Q3 | $3.21M | Buy |
258,724
+57,852
| +29% | +$765K | ﹤0.01% | 3608 |
|
|
2019
Q2 | $3.23M | Buy |
200,872
+11,802
| +6% | +$264K | ﹤0.01% | 3640 |
|
|
2019
Q1 | $5.95M | Sell |
189,070
-13,903
| -7% | -$395K | ﹤0.01% | 3347 |
|
|
2018
Q4 | $6.67M | Buy |
202,973
+198,036
| +4,011% | +$6.52M | ﹤0.01% | 3287 |
|
|
2018
Q3 | $151K | Hold |
4,937
| – | – | ﹤0.01% | 4379 |
|
|
2018
Q2 | $132K | Buy |
+4,937
| New | +$130K | ﹤0.01% | 4405 |
|
Other funds holding AUTL
MCO
SP
AC
TAM
FLSM
LCM
BlackRock's AUTL Position: Q2 2026 in Review
BlackRock increased its Autolus Therapeutics (AUTL) stake by 8.3% in Q2 2026, buying an estimated $193K and bringing the position to 1,603,458 shares worth $2.57M. The position accounts for ﹤0.01% of the portfolio, ranked #4097.
BlackRock first reported a position in AUTL in Q2 2018 and has held it in 33 quarters since. The position peaked at $25.9M in Q1 2024. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.
- BlackRock held 1,603,458 shares of Autolus Therapeutics worth $2.57M as of Q2 2026.
- BlackRock bought 122,726 Autolus Therapeutics shares in Q2 2026, an estimated $193K.
- Autolus Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4097 holding.
- BlackRock first reported a position in Autolus Therapeutics in Q2 2018 and has held it in 33 quarters since.
- BlackRock's Autolus Therapeutics position peaked at $25.9M in Q1 2024.
- 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.